|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | |||||||||||||||||||
| Current assets: | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Investment securities at fair value | |||||||||||||||||||
| Receivables | |||||||||||||||||||
| Agent receivables, net | |||||||||||||||||||
| Income taxes receivables, net | |||||||||||||||||||
| Restricted cash and cash equivalents | |||||||||||||||||||
| Other current assets | |||||||||||||||||||
| Total current assets | |||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||||
| Long-term investments (includes $3,183 and $4,399 at fair value) | |||||||||||||||||||
| Contract assets, net | |||||||||||||||||||
| Goodwill | |||||||||||||||||||
| Other intangible assets, net | |||||||||||||||||||
| Deferred income taxes, net | |||||||||||||||||||
| Equity-method investments | |||||||||||||||||||
| Other assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY: | |||||||||||||||||||
| Current liabilities: | |||||||||||||||||||
| Current operating lease liabilities | |||||||||||||||||||
| Current portion of antitrust litigation settlements | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Income taxes payable, net | |||||||||||||||||||
| Commissions payable | |||||||||||||||||||
| Accrued salaries and benefits | |||||||||||||||||||
| Contract liabilities | |||||||||||||||||||
| Other current liabilities | |||||||||||||||||||
| Total current liabilities | |||||||||||||||||||
| Deferred income taxes, net | |||||||||||||||||||
| Notes payable and other obligations less current portion | |||||||||||||||||||
| Fair value of the derivative embedded within convertible debt | |||||||||||||||||||
| Non-current operating lease liabilities | |||||||||||||||||||
| Contract liabilities | |||||||||||||||||||
| Antitrust litigation settlements | |||||||||||||||||||
| Other liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Stockholders' equity: | |||||||||||||||||||
| Preferred stock, par value $0.01 per share, 10,000,000 shares authorized | |||||||||||||||||||
| Common stock, shares issued (in shares) | |||||||||||||||||||
| Common stock, par value $0.01 per share, 250,000,000 shares authorized, 90,890,473 and 88,247,942 shares issued and outstanding | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total Douglas Elliman Inc. stockholders' equity | |||||||||||||||||||
| Non-controlling interest | |||||||||||||||||||
| Total stockholders' equity | |||||||||||||||||||
| Total liabilities and stockholders' equity | |||||||||||||||||||
Loading...
